Dexcom to promote COO Jake Leach to CEO

Dexcom (Nadsaq:DXCM) announced today that Jake Leach will succeed Kevin Sayer as CEO, effective Jan. 1, 2026.

Leach, the company’s president and COO, will take over the corner office as part of the company’s planned succession process. Sayer, who served in the CEO role for more than a decade after assuming the post in January 2015, intends to continue working closely with Leach during the transition period. He also plans to remain on the company’s board as its executive chair at the point of transition.

The company announced the planned CEO transition in its second-quarter earnings report. Read about the results HERE.

Sayer originally joined Dexcom’s board in November 2007, then became president in 2011. He held the role of COO, like Leach, until his promotion to CEO in 2015.

“Today’s announcement of Jake’s transition to the role of chief executive officer reflects the Board’s comprehensive succession planning and their confidence in Jake’s leadership throughout his tenure. We are confident that he is the right leader to build on Dexcom’s momentum and extend the company’s growth well into the future,” said Kevin Sayer.

Dexcom’s CTO Girish Naganathan will speak about the future of connected health at DeviceTalks West, Oct. 15–16, 2025 in Santa Clara, California. Register at West.DeviceTalks.com.

Leach has spent 21 years at the company, leading teams responsible for developing multiple generations of continuous glucose monitors (CGMs). Those include the current-generation G7 and Stelo over-the-counter offerings. He joined the company in 2004 to lead the development of sensor electronics for its first commercial CGMs.

In 2022, Leach took over as COO at Dexcom. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments.

Then, in May of this year, the company promoted him to the expanded role of president and COO. That promotion saw him take over additional responsibilities like oversight for strategy and corporate development.

“I am humbled and excited to transition into the CEO role at this critical time in Dexcom’s history,” said Jake Leach. “I look forward to leading our incredible teams as we advance access to our technology to more people around the world, empowering better metabolic health for our customers and creating value for our stakeholders.”

Leach’s appointment did not come as a shock to BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang as well.

“We are not surprised by the choice of Mr. Leach for this role, as he has been promoted a couple of times over the past several years and has become increasingly visible and Street-facing,” the analysts wrote. “The timing and advance notice of this succession also seem appropriate to us, and we expect it to be a smooth transition.”